17,261 trials
Cervical Carcinoma · Cervical Intraepithelial Neoplasia Grade 2/3 · Stage 0 Cervical Cancer
Primary: Histologic Regression — 40; 34.1 percentage of participants
Differentiated Thyroid Gland Carcinoma · Recurrent Thyroid Gland Carcinoma · Refractory Thyroid Gland Carcinoma
Primary: Objective Response Rate, Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST) — 9; 7 Participants — p=<0.10
Mucopolysaccharidosis Type I · Mucopolysaccharidosis Type II · Mucopolysaccharidosis Type VI
Primary: Children's Health Questionnaire - Parent Form 50 Bodily Pain Standardized Score — 1.4; 1.0 units on a scale
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Treatment (SVR12) — 100.0; 96.0 percentage of particpants
Acute Myeloid Leukemia
Primary: Number of Participants by Best Clinical Response Experienced — 20; 6; 6; 7 Participants
Acne Vulgaris
Primary: Logarithmic Change in Colony Counts of Facial Propionibacterium Acnes — -1.0376; -0.4614 log change in colony forming units
Breast Cancer
Primary: Progression-free Survival — 16 Months
Allergic Conjunctivitis
Primary: Ocular Itching at Onset of Action (15 Minutes Post-dose) — 1.33; 0.99; 2.11; 2.90 units on a scale
Hepatitis C
Primary: A Comparison of the Percentage of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of Treatment. — 28.8; 31.5…
Vitreous Hemorrhage
Primary: Rate of Resolved Post-operative Vitreous Hemorrhage. — 6; 5 Participants
Large Polyps in the Gastrointestinal Tract
Primary: Duration of the Submucosal Cushion
Multiple Myeloma
Primary: Number of Patients Exhibiting a Given Overall Response as Determined by Investigator — 0; 0; 0; 0 participants
Schizophrenia · Schizoaffective Disorder
Primary: Final Positive and Negative Symptom Scale (PANSS) — 54.4; 60.2 PANSS Total — p=.38
Breast Neoplasms · Neoplasms
Primary: 16-week Progression Free Survival — 58.2; 77.8 percentage of participants
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients